Artivion Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Artivion han disminuido a una tasa media anual de -40%, mientras que en la industria Medical Equipment los beneficios crecieron en un 8.7% anualmente. Los ingresos han ido creciendo a una tasa media de 6.5% al año.

Información clave

-40.0%

Tasa de crecimiento de los beneficios

-38.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	6.5%
Rentabilidad financiera	-3.3%
Margen neto	-2.6%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Dec 18

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Sep 29

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Sep 27

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Aug 04

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jun 27

Is Artivion (NYSE:AORT) Using Too Much Debt?

Mar 25

CryoLife (NYSE:CRY) Has A Somewhat Strained Balance Sheet

Dec 08

Desglose de ingresos y gastos

Cómo gana y gasta dinero Artivion. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:AORT Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	368	-10	188	28
31 Dec 23	354	-31	185	29
30 Sep 23	340	-24	180	29
30 Jun 23	329	-28	175	35
31 Mar 23	320	-29	171	36
31 Dec 22	314	-19	166	39
30 Sep 22	314	-41	170	40
30 Jun 22	309	-17	168	38
31 Mar 22	305	-15	163	38
31 Dec 21	299	-15	161	36
30 Sep 21	287	2	145	33
30 Jun 21	280	-12	141	28
31 Mar 21	258	-13	135	26
31 Dec 20	253	-17	137	24
30 Sep 20	255	-14	143	23
30 Jun 20	258	-11	143	23
31 Mar 20	275	-5	145	24
31 Dec 19	276	2	143	23
30 Sep 19	274	2	148	24
30 Jun 19	271	3	140	23
31 Mar 19	268	1	140	23
31 Dec 18	263	-3	141	23
30 Sep 18	248	-5	128	23
30 Jun 18	227	-5	127	22
31 Mar 18	207	-2	116	21
31 Dec 17	190	4	101	19
30 Sep 17	182	9	100	17
30 Jun 17	183	11	96	16
31 Mar 17	182	10	94	15
31 Dec 16	180	11	92	13
30 Sep 16	175	10	78	12
30 Jun 16	167	9	76	11
31 Mar 16	155	7	74	11
31 Dec 15	146	4	72	10
30 Sep 15	143	3	74	10
30 Jun 15	144	3	76	9
31 Mar 15	143	6	74	8
31 Dec 14	145	7	74	9
30 Sep 14	142	14	72	9
30 Jun 14	141	15	69	9
31 Mar 14	140	15	68	9
31 Dec 13	141	16	68	8
30 Sep 13	138	9	68	8
30 Jun 13	135	7	68	8

Ingresos de calidad: AORT actualmente no es rentable.

Margen de beneficios creciente: AORT actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: AORT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 46.5% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de AORT en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: AORT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (2.4%).

Rentabilidad financiera

Alta ROE: AORT tiene una rentabilidad financiera negativa (-3.26%), ya que actualmente no es rentable.

Artivion Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Artivion, Inc. to Report Q1, 2024 Results on May 06, 2024

Artivion, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion, Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Artivion, Inc. to Report Q1, 2024 Results on May 06, 2024

Artivion, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Chairman recently sold US$262k worth of stock

Chairman recently sold US$242k worth of stock

Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 880%

Price target increased by 11% to US$25.15

Artivion, Inc. Provides Earnings Guidance for the Year 2024

Artivion, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Artivion, Inc. announced that it expects to receive $350 million in funding

Is Artivion (NYSE:AORT) Using Too Much Debt?

Senior VP notifies of intention to sell stock

Artivion Stock: A First Assessment

VP & Chief Accounting Officer notifies of intention to sell stock

Artivion, Inc. Announces Chief Financial Officer Changes

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion, Inc. Announces Completion of Enrollment in PERSEVERE Trial

Consensus EPS estimates fall by 29%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. Revises Earnings Guidance for the Year 2023

Artivion, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Artivion, Inc. Announces Data from On-X Aortic Heart Valve Low INR Post-Market Study Presented in A Late-Breaking Science Session At the 37European Association for Cardio-Thoracic Surgery Annual Meeting

Artivion, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Senior Vice President of Operations recently sold US$248k worth of stock

Price target increased by 10% to US$24.90

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Chairman recently sold US$293k worth of stock

Artivion, Inc. Provides Earnings Outlook for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Insider exercised options to buy US$115k worth of stock.

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Artivion, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Price target decreased to US$23.13

Price target decreased to US$23.13

Artivion, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 profit in 3Q 2021)

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Artivion, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Artivion, Inc. Announces the Appointment of Elizabeth A. Hoff to Board of Directors

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Price target decreased to US$26.96

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

Insider recently sold US$125k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. Provides Financial Guidance for the Year 2022

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Artivion Initiates Enrollment in PERSEVERE Clinical Trial

Artivion, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Is Artivion (NYSE:AORT) Using Too Much Debt?

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$29.75

Insufficient new directors

Artivion, Inc. to Report Q1, 2022 Results on May 05, 2022

Artivion, Inc., Annual General Meeting, May 18, 2022